Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
XNPT's Cash to Debt is ranked higher than
89% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. XNPT: No Debt )
XNPT' s 10-Year Cash to Debt Range
Min: 23.99   Max: No Debt
Current: No Debt

Equity to Asset 0.79
XNPT's Equity to Asset is ranked higher than
81% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. XNPT: 0.79 )
XNPT' s 10-Year Equity to Asset Range
Min: -1.59   Max: 0.88
Current: 0.79

-1.59
0.88
F-Score: 2
Z-Score: -1.30
M-Score: -1.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1076.95
XNPT's Operating margin (%) is ranked higher than
55% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. XNPT: -1076.95 )
XNPT' s 10-Year Operating margin (%) Range
Min: -5504.8   Max: 18.25
Current: -1076.95

-5504.8
18.25
Net-margin (%) -1080.15
XNPT's Net-margin (%) is ranked higher than
55% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. XNPT: -1080.15 )
XNPT' s 10-Year Net-margin (%) Range
Min: -4876   Max: 24.77
Current: -1080.15

-4876
24.77
ROE (%) -159.95
XNPT's ROE (%) is ranked higher than
52% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. XNPT: -159.95 )
XNPT' s 10-Year ROE (%) Range
Min: -159.95   Max: 22.46
Current: -159.95

-159.95
22.46
ROA (%) -109.35
XNPT's ROA (%) is ranked higher than
52% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. XNPT: -109.35 )
XNPT' s 10-Year ROA (%) Range
Min: -109.35   Max: 16.31
Current: -109.35

-109.35
16.31
ROC (Joel Greenblatt) (%) -3355.33
XNPT's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. XNPT: -3355.33 )
XNPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3355.33   Max: 305.89
Current: -3355.33

-3355.33
305.89
Revenue Growth (%) 23.60
XNPT's Revenue Growth (%) is ranked higher than
91% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. XNPT: 23.60 )
XNPT' s 10-Year Revenue Growth (%) Range
Min: -72.6   Max: 126.3
Current: 23.6

-72.6
126.3
EBITDA Growth (%) -11.70
XNPT's EBITDA Growth (%) is ranked higher than
72% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. XNPT: -11.70 )
XNPT' s 10-Year EBITDA Growth (%) Range
Min: -54.3   Max: -7.9
Current: -11.7

-54.3
-7.9
EPS Growth (%) -12.30
XNPT's EPS Growth (%) is ranked higher than
75% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. XNPT: -12.30 )
XNPT' s 10-Year EPS Growth (%) Range
Min: -52.3   Max: -7.4
Current: -12.3

-52.3
-7.4
» XNPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

XNPT Guru Trades in Q2 2013

Paul Tudor Jones 53,300 sh (New)
PRIMECAP Management 128,000 sh (+0.79%)
Steven Cohen Sold Out
Jim Simons 110,600 sh (-65.25%)
» More
Q3 2013

XNPT Guru Trades in Q3 2013

PRIMECAP Management 128,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q4 2013

XNPT Guru Trades in Q4 2013

Jim Simons 59,312 sh (New)
PRIMECAP Management 128,000 sh (unchged)
» More
Q1 2014

XNPT Guru Trades in Q1 2014

Steven Cohen 16,300 sh (New)
Paul Tudor Jones 41,668 sh (New)
PRIMECAP Management 128,000 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with XNPT

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2012-06-30 New Buy$4.08 - $6.15 $ 4.15-20%125000
George Soros 2011-12-31 Sold Out 0.0016%$3.57 - $6.34 $ 4.15-16%0
George Soros 2011-09-30 Reduce -38.17%$5.95 - $7.72 $ 4.15-41%16200
George Soros 2011-06-30 New Buy$6.05 - $9.31 $ 4.15-45%26200
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.30
XNPT's P/B is ranked higher than
87% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. XNPT: 2.30 )
XNPT' s 10-Year P/B Range
Min: 1.71   Max: 13.19
Current: 2.3

1.71
13.19
P/S 19.70
XNPT's P/S is ranked higher than
70% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. XNPT: 19.70 )
XNPT' s 10-Year P/S Range
Min: 2.65   Max: 111.17
Current: 19.7

2.65
111.17
EV-to-EBIT -1.64
XNPT's EV-to-EBIT is ranked higher than
58% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. XNPT: -1.64 )
XNPT' s 10-Year EV-to-EBIT Range
Min: 50.9   Max: 9027.3
Current: -1.64

50.9
9027.3
Current Ratio 8.07
XNPT's Current Ratio is ranked higher than
86% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. XNPT: 8.07 )
XNPT' s 10-Year Current Ratio Range
Min: 2.31   Max: 12.21
Current: 8.07

2.31
12.21
Quick Ratio 7.98
XNPT's Quick Ratio is ranked higher than
86% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. XNPT: 7.98 )
XNPT' s 10-Year Quick Ratio Range
Min: 2.31   Max: 12.21
Current: 7.98

2.31
12.21

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.80
XNPT's Price/Net Cash is ranked higher than
95% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. XNPT: 2.80 )
XNPT' s 10-Year Price/Net Cash Range
Min: 2.06   Max: 16.33
Current: 2.8

2.06
16.33
Price/Net Current Asset Value 2.70
XNPT's Price/Net Current Asset Value is ranked higher than
95% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. XNPT: 2.70 )
XNPT' s 10-Year Price/Net Current Asset Value Range
Min: 2.06   Max: 16
Current: 2.7

2.06
16
Price/Tangible Book 2.30
XNPT's Price/Tangible Book is ranked higher than
91% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. XNPT: 2.30 )
XNPT' s 10-Year Price/Tangible Book Range
Min: 1.8   Max: 12.9
Current: 2.3

1.8
12.9
Price/Median PS Value 1.30
XNPT's Price/Median PS Value is ranked higher than
76% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. XNPT: 1.30 )
XNPT' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 6.41
Current: 1.3

0.2
6.41
Earnings Yield (Greenblatt) 3.70
XNPT's Earnings Yield (Greenblatt) is ranked higher than
63% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. XNPT: 3.70 )
XNPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 3.7
Current: 3.7

1.3
3.7
Forward Rate of Return (Yacktman) -48.67
XNPT's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. XNPT: -48.67 )
XNPT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -22.2   Max: -16.3
Current: -48.67

-22.2
-16.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LMW.Germany
XenoPort, Inc., is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates with an initial focus on neurological disorders. Its product candidates are prodrugs that are typically created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. Its marketed product and each of its product candidates are orally available, patented or patentable molecules that address potential markets with clear unmet medical needs. Its marketed product is approved in the United States, where it is known as Horizant (gabapentin enacarbil) Extended-Release Tablets, and in Japan, where it is known as Regnite (gabapentin enacarbil) Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic (nerve) pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with RLS. Gabapentin enacarbil is licensed to Astellas Pharma Inc. in Japan and five other Asian countries. It has three product candidates in clinical development. Its product candidate, arbaclofen placarbil, or AP, is a potential treatment for patients with spasticity. It is conducting a pivotal Phase 3 clinical trial under a Special Protocol Assessment, or SPA, with the FDA for AP as a potential treatment for spasticity in patients with multiple sclerosis, or MS. Its second product candidate, XP21279, is a potential treatment for patients with advanced idiopathic Parkinson's disease. In 2011, it completed a Phase 2 clinical trial of XP21279/carbidopa compared to patient-optimized doses of Sinemet (levodopa/carbidopa) in patients with Parkinson's disease who experience motor fluctuations. It is evaluating its third product candidate, XP23829, in Phase 1 studies with healthy subjects to determine its safety and pharmacokinetic profile. GSK holds commercialization rights for Horizant in the United States during a transition period ending on April 30, 2013. The Company face competition from established pharmaceutical and biotechnology companies, including generic competitors, as well as from academic institutions, government agencies and private and public research institutions. The Company is subject to regulation by regi
» More Articles for XNPT

Headlines

Articles On GuruFocus.com
comment on XNPT Mar 15 2013 
comment on XNPT Mar 06 2013 
XenoPort Inc. Reports Operating Results (10-Q) Nov 09 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2010 
XenoPort Inc. Reports Operating Results (10-Q) May 10 2010 
Xenoport - A Shaking Ham Hock Feb 07 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2009 
XenoPort Reports Second Quarter Financial Results Aug 05 2009 
Weekly Top Insider Buys: Alcoa Inc., ABM Industries Inc., Valhi Inc., XenoPort Inc., and Methode Ele Jul 11 2009 
XenoPort Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
XenoPort to Release Second Quarter Financial Results on August 6, 2014 Jul 22 2014
XenoPort to Release Second Quarter Financial Results on August 6, 2014 Jul 22 2014
Immune Pharma: A Top-Pick Based On Pipeline And Valuation Jul 09 2014
XenoPort entitled to $20M upfront payment on license pact Jun 24 2014
XENOPORT INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial... Jun 24 2014
XenoPort's XP23829 in Phase II Study Jun 24 2014
XENOPORT INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Jun 16 2014
Stockholders Elect ALL Three XenoPort Director Nominees at Annual Meeting Jun 11 2014
XenoPort to Present at the 2014 Wells Fargo Healthcare Conference Jun 09 2014
XenoPort Urges Stockholders to Vote "FOR ALL" XenoPort Director Nominees on the WHITE Proxy Card Jun 06 2014
CEO Has Special Incentive to Spend on Horizant, Says Clinton Group Jun 05 2014
XenoPort Mails Letter to Stockholders Highlighting ISS’s Recommendation That XenoPort Stockholders... Jun 03 2014
Second Independent Proxy Advisory Firm Recommends that XenoPort Stockholders Vote “FOR ALL”... Jun 02 2014
XenoPort to Present New Pooled Data Analyses on HORIZANT (gabapentin enacarbil) at the 2014 SLEEP... Jun 02 2014
XenoPort says ISS recommends investors vote for all director nominees May 30 2014
Leading Independent Proxy Advisory Firm ISS Recommends XenoPort Stockholders Vote FOR ALL XenoPort... May 30 2014
Xenoport, Inc. (XNPT) Soars: Stock Up 5.9% May 29 2014
XenoPort to Present at the Jefferies 2014 Global Healthcare Conference May 27 2014
Clinton Group sends letter to XenoPort shareholders May 22 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide